Stockscreener 앱 받기
16.23
5.31%
-0.91
시장 영업 전:
16.23
전일 마감가:
$17.14
열려 있는:
$17.08
하루 거래량:
2.64M
Relative Volume:
1.00
시가총액:
$3.03B
수익:
-
순이익/손실:
$-451.71M
주가수익비율:
-5.0308
EPS:
-3.2261
순현금흐름:
$-462.19M
1주 성능:
-6.21%
1개월 성능:
-37.82%
6개월 성능:
-9.18%
1년 성능:
+23.05%
1일 변동 폭
$16.18
$17.08
1주일 범위
$16.18
$18.15
52주 변동 폭
$11.92
$27.30
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
16.23 | 3.03B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.82 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.11 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
945.82 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.00 | 41.29B | 5.76B | 514.49M | 1.10B | 4.4813 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-25 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com
New Dyne hires receive stock tied to 278,100 shares - stocktitan.net
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative? - Yahoo Finance
What Dyne Therapeutics Stock One Year Trial Data Means For Shareholders - simplywall.st
DYN: Strong clinical progress and launch readiness position the company for leadership in neuromuscular disease therapies - TradingView
Dyne Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Stocktwits
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN) - theglobeandmail.com
Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com Canada
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Wall Street Slashes Dyne Therapeutics Targets After Novartis DM1 Trial Failure - finance.biggo.com
DYN Maintained by Morgan Stanley -- Price Target Lowered to $36 - GuruFocus
Dyne Therapeutics Shares Plummet After Novartis Phase 3 Trial Failure - Intellectia AI
Dyne Therapeutics CMO Kerr Douglas Sells 5,035 Shares Between $18.88 and $24.35 (NASDAQ: DYN) - kalkinemedia.com
DYN Downgraded by JP Morgan -- Price Target Lowered to $10.00 - GuruFocus
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says - Moomoo
DYN Maintains Rating by RBC Capital -- Price Target Lowered to $30 - GuruFocus
Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com Canada
Dyne Therapeutics falls 16% after Novartis DM1 trial failure raises doubts on RNA therapy success - Pluang
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha
RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Nigeria
Dyne Therapeutics (DYN) officer plans $106K stock sale - Stock Titan
Dyne Therapeutics (Nasdaq: DYN) officer to sell 3,000 shares from RSUs - stocktitan.net
Dyne Therapeutics (DYN) CCO’s tax sales leave 102,966 unvested RSUs - stocktitan.net
Tax-driven stock sale by Dyne (DYN) medical chief - Stock Titan
Dyne Therapeutics (DYN) CEO sells shares to cover taxes - Stock Titan
Raymond James sets Dyne Therapeutics price targ... - Pluang
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling - Benzinga
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Nigeria
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings - Investing News Network
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - rttnews.com
Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase I - GuruFocus
Dyne Therapeutics (DYN) Faces Market Pressure After Novartis DM1 - GuruFocus
Dyne Therapeutics (DYN) Faces Pressure After Novartis Trial Fail - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Yahoo Finance
Dyne Therapeutics stock faces pressure after rival drug fails trial - Investing.com
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed - Yahoo Finance
Why is Dyne Therapeutics stock plummeting today? By Investing.com - Investing.com Nigeria
Why is Dyne Therapeutics stock plummeting today? - Investing.com
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History - Yahoo Finance
Dyne Therapeutics (NASDAQ: DYN) officer plans $121,745 share sale - Stock Titan
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy at 27th Annual NMSG Scientific Meeting - Investing News Network
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting - The Manila Times
Dyne Therapeutics Announces Preclinical Data Supporting Four DMD Exon-Skipping Candidates Advancing Into IND-Enabling Studies - Quiver Quantitative
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.49%
자본화:
|
볼륨(24시간):